Oncolytics Biotech

Update in progress

ONCY (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing oncology treatments. It advances pelareorep, an intravenously delivered immunotherapeutic agent for gastrointestinal tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. The company collaborates with Roche to supply the immune checkpoint inhibitor atezolizumab for ongoing sponsored studies. Founded in 1998, it is based in San Diego, California.

Company score

Sentiment: 0.26; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.18; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive